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Summary
Objective: Pleiotrophin (PTN) is a 15.3 kDa heparin-binding peptide, which is expressed in mesodermal and neuroectodermal cells during
development, but rarely in adult tissues. In fetal or juvenile cartilage, PTN is an abundant protein and appears to be involved in chondrocyte
differentiation. Since developmentally regulated factors often re-appear in the disease state, we examined PTN expression in cartilage and
synovial fluid of patients with osteoarthritis (OA).
Methods: PTN mRNA and protein expression was assayed by reverse transcriptase-polymerase chain reaction (RT-PCR) and Western blot,
the protein was localized by immunohistochemistry and quantified by enzyme-linked immunoassay (ELISA).
Results: PTN was undetectable in normal adult cartilage, but PTN mRNA and protein were found in OA. In cartilage from the tibial plateaus
of OA patients, PTN could be immunostained in clusters of superficial chondrocytes. In the synovial fluids of OA patients, PTN concentrations
were elevated in earlier OA stages, but rarely in late OA stages. Chondrosarcomas were PTN-immunonegative.
Conclusions: In addition to certain types of cancer, the embryonic growth and differentiation factor PTN is found also in adults in inflammatory
diseases. In OA, PTN is especially expressed in early stages, and PTN concentrations in the synovial fluid could serve as a marker for the
progress of the disease. PTN might be involved in cartilage repair in OA, in particular, in earlier stages.
© 2003 OsteoArthritis Research Society International. Published by Elsevier Science Ltd. All rights reserved.
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Introduction
Pleiotrophin (PTN), also known as heparin-binding growth-
associated molecule (HB-GAM), heparin-binding growth
factor 8, heparin-binding neurotrophic factor (HBNF), and
osteoblast-specific protein-1 (OSF-1), is a 136-amino acid
(15.3 kDa) secreting growth/differentiation cytokine that is
developmentally regulated1,2. Mature PTN is a non-
glycosylated, lysine-rich peptide that migrates anomalously
as an 18 kDa band in SDS-PAGE (therefore also termed as
p18; see reference 3) and is derived from a 168 residue
precursor with a 32-amino acid signal sequence. PTN is a
differentiation or growth factor for various cell types (there-
fore termed pleiotrophin); it promotes angiogenesis, stimu-
lates neurite outgrowth from cultured neurons, induces a
bipolar form of glial cell precursors, and induces cell
migration4–8. Together with midkine (MK) it forms a family
of heparin-binding proteins that are normally expressed
during embryogenesis, but only at low levels in healthy
adult tissues9. However, PTN is re-expressed in some
human tumors, e.g., meningiomas10, part of breast can-
cers11, or pancreatic cancers12, and there is some evi-
dence that PTN is involved in tumorigenesis by enhancing
angiogenesis11–13.
In fetal or juvenile cartilage, PTN is an abundant
protein14–16 and appears to be implicated in the regulation
of proteoglycan synthesis by chondrocytes17 and probably
controls—together with other angiogenesis factors—the
invasion of blood vessels into hypertrophic cartilage16.
Since genes expressed during development often re-
appear in the disease state, we investigated the formation
of PTN in OA cartilage and synovial fluid.
Materials and methods
PEPTIDES AND ANTIBODIES
Goat anti-PTN (affinity purified IgG fraction, code AF-
252-PB) and biotinylated anti-PTN (code BAF252) were
purchased from R&D Systems (Minneapolis, MN), second-
ary antibodies were from Sigma (Taufkirchen, Germany).
Recombinant human PTN was from PreproTech (Rock Hill,
NJ).
TISSUES AND SYNOVIAL FLIUDS
Tibial plateaus were obtained from late OA patients
(71±8 years; five men and five women) who underwent
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joint replacements at the Department of Orthopedic Sur-
gery of the Christian-Albrechts-University in Kiel Germany.
Normal control samples without morphological signs of OA
and early OA samples (45±11 years) were obtained from
volunteer body donors (Department of Anatomy). Synovial
fluids were obtained from arthroscopies at the ‘Ambulantes
Operationszentrum am Eichkoppelweg’ Kiel, Germany, and
from volunteer body donors (Department of Anatomy).
REVERSE TRANSCRIPTASE-POLYMERASE CHAIN REACTION
(RT-PCR)
RNA was isolated with the guanidinium thiocyanate
method, digested with DNase, cDNA was generated, and
RT-PCR was performed with the primers 5′-CCT-TCT-
TGG-CAT-TCA-TTT-TCA-TAC-3′ (sense) and 5′-GAG-
GTT-TGG-GGT-TGG-TCA-GT-3′ (antisense) at an
annealing temperature of 60°C with 40 cycles according to
previous protocols18. The RT-PCR product was identified
by agarose gel electrophoresis and by direct sequencing
with the ‘DyeDeoxy Terminator Cycle Sequencing’ method
using an ABI PRISM 310 Genetic Analyzer (Applied Bio-
systems, Foster City, CA) as described19. A separate
RT-PCR for glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) with an intron-spanning primer pair served as
control for intactness of RNA and absence of contaminating
DNA19.
WESTERN BLOT AND IMMUNOHISTOCHEMISTRY
Western blots from cartilage homogenates (homog-
enized with a blender in 0.14 M NaCl 10 mM Hepes, pH
7.4) were obtained after separation in 15% SDS-PAGE
gels, blotted onto nitrocellulose membranes followed by
chemoluminescence detection20.
For immunohistochemistry, cartilage samples were fixed
with 4% formaldehyde in phosphate-buffered saline (PBS;
30 min room temperature), decalcified in 10% EDTA for
several days until X-ray examination revealed complete
decalcification, and were then dehydrated and embedded
in paraffin. Deparaffinized 8-µm sections were dewaxed,
etched with hyaluronidase and pronase18, washed (3× with
PBS), incubated with anti-PTN (1:500 in PBS overnight at
4°C), washed (3×), incubated with peroxidase-labeled anti-
goat IgG (1:250 in PBS; 30 min room temperature), washed
(3×), stained with 3-amino-9-ethylcarbazole/H2O2 (7 min
room temperature; universal peroxidase detection kit,
Coulter-Immunotech, Hamburg, Germany), and finally
counterstained with hemalum.
ENZYME-LINKED IMMUNOASSAY (ELISA)
The PTN-ELISA was performed with Nunc-Immuno Maxi-
sorb plates (Nunc, Roskilde, Denmark) coated with anti-
PTN (50 ng/well, overnight at room temperature) that were
washed three times with 0.05% Tween 20 in PBS (washing
buffer), blocked with 1% BSA in PBS (1 h room tempera-
ture), and washed. Wells were incubated with samples,
standards or blanks (300 µl, diluted with PBS; 2 h room
temperature), washed three times, incubated with biotin-
ylated anti-PTN (50 ng/well) for 2 h at room temperature (or
overnight at 4°C), washed three times, incubated with
streptavidin–peroxidase (1:20 000 of a 1.25 mg/ml solution;
Zymed code 43-4323) for 20 min at room temperature, and
finally, were washed three times and incubated with 100 µl
tetramethybenzidine-H2O2 (TMB substrate kit code 34021
from Pierce, Rockford, IL). After 30 min at room tempera-
ture, the reaction was stopped by addition of 50 µl 0.5 M
H2SO4, and the yellow dye measured at 450 nm. The
assay was linear for 0.05–1.5 ng PTN (detection limit about
0.02 ng). Statistical significance was evaluated by the
t-test.
Results
PTN CAN BE DETECTED IN OA CARTILAGE BY RT-PCR AND
WESTERN BLOT
In RT-PCR experiments with sequence-specific primers,
we could detect PTN mRNA in homogenates of cartilage
from the tibial plateau from OA patients, but not from that of
control adult cartilage (Fig. 1). Cartilage from OA patients
Fig. 1. PTN mRNA and protein can be detected by RT-PCR (top)
and Western blot (bottom) in OA patients, but not in normal adult
cartilage. C, cartilage from an adult control sample without signs of
OA; OA, samples from OA cartilage with severe (late OA) or
moderate (early OA) degenerative changes. RT-PCR: RNA was
extracted from the tibia plateau cartilage, reverse transcribed,
amplified with primers specific for PTN or GAPDH (control for
intactness of RNA and absence of contaminating DNA), and
products were separated by agarose gel electrophoresis and
stained with ethidium bromide. The PTN-PCR products corre-
spond to the predicted size of 402 bp (base pairs) as estimated
from the 100 bp markers (M); their identity was further verified by
sequencing. Examples of several experiments from six patients
each of both sexes of early OA (Mankin’s score, 1–7) and of late
OA (Mankin’s score, 8–14) yielding identical results. Western blot:
Cartilage was homogenized and equal amounts of denatured and
reduced protein were separated on 15% SDS-PAGE gels, blotted
onto nitrocellulose membranes that were stained with anti-PTN
followed by chemiluminescence detection. PTN molecular mass
was calculated from the position of markers (soybean trypsin
inhibitor, 20.1 kDa; bovine α-lactalbumin, 14.2 kDa).
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with severe (late OA) degenerative changes generally
yielded a stronger signal than tissue from OA patients with
moderate ones. No apparent differences were observed
between sexes and age. In Western blot experiments,
similar results were obtained for the expression PTN
protein that could be stained as an 18 kDa band in
homogenates of cartilage from OA patients. However,
homogenates of normal adult cartilage yielded no signal.
Again, in homogenates from patients with moderate degen-
erative changes (early OA patient), the band was stronger
than in those with more severe changes.
PTN CONCENTRATIONS ARE ELEVATED IN THE SYNOVIAL FLUIDS
OF OA PATIENTS WITH MODERATE CHANGES
To quantify the differences observed in PTN expression
between OA patients with moderate and severe degenera-
tive changes, we developed a sensitive ELISA for PTN, and
measured PTN in the synovial fluids of OA patients that
underwent a synovialectomy or in that from volunteer body
donors. According to their clinical signs, the patients were
ranked into two groups, early (Mankin’s score 1–7) and late
stages (Mankin’s score 8–14) of OA. Apart from one
exception, PTN concentrations in the synovial fluids from
early OA patients were higher than in those from late OA
patients (Fig. 2). Most values from late OA were not, or only
weakly, elevated when compared with the healthy sample.
PTN CAN BE IMMUNOSTAINED IN CHONDROCYTES OF OA
PATIENTS
In accordance with the above results, OA cartilage, but
not the normal adult cartilage from the tibial plateau, could
be immunostained for PTN (Fig. 3). Clusters of chondro-
cytes in the superficial zone of OA cartilage were immuno-
positive for PTN whereas those in deeper zones were
immunonegative [Fig. 3(A,B)]. Chondrocytes in the carti-
lage of adult specimen (cadaver) without signs of OA
showed no immunoreaction for PTN [Fig. 3(C)]. Control
experiments either with antibody inactivated with recom-
binant PTN or with omitting the primary antibody yielded no
staining (not shown).
Since developmentally expressed factors are often re-
expressed in tumors, we analyzed sections from chondro-
sarcomas grades I, II and III for PTN. All sections tested
(four to five of the individual samples of each grade) were
completely immunonegative despite the fact that positive
control samples run in parallel showed strong immuno-
reaction.
Fig. 2. PTN concentrations in the synovial fluid are higher in earlier
than the later stages of OA. Values from triplicate ELISA determi-
nations of samples from individual patients are depicted together
with means plus standard deviations of the collective. Patients
were staged according to the clinical symptoms. Statistical signifi-
cance: early vs late OA or controls (p<0.05).
Fig. 3. PTN can be immunostained in OA, but not in normal adult cartilage. (A, B) In cartilage from the tibial plateau of an OA patient with
moderate degenerative changes (Mankin grade 8), PTN can be detected in clusters of superficial chondrocytes. (C) PTN immunostaining
negative results in normal adult cartilage. Bar: 100 µm (A, C); 10 µm (B); original magnification, 200-fold (A, C), 650-fold (B).
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Discussion
Chronic inflammation is characterized by the production
of various cytokines and angiogenic factors, e.g., in OA
they are: tumor necrosis factor-α (TNF-α), interleukin-1, -6,
and vascular endothelial growth factor (VEGF)18,21–23. We
now discuss that PTN, a developmentally expressed
growth and differentiation factor, is re-expressed and up-
regulated in OA chondrocytes whereas it is absent in
cartilage from healthy adults. In contrast, PTN is highly
expressed in fetal epiphyseal cartilage where it appears to
function as a differentiation factor and an angiogenesis
factor14–16.
PTN has been reported to be mitogenic for endothelial
and epithelial cells as well as for the fibroblasts4,5,24.
However, in juvenile chondrocytes, recombinant PTN has
been reported to inhibit 3H-thymidine incorporation, but
stimulate extracellular matrix synthesis, in particular that of
biglycan and collagen type II, but not of decorin and
aggrecan17. Therefore, in embryonic/juvenile cartilage,
PTN appears to be a differentiation factor (apart from a
possible function as angiogenesis factor). Re-expression of
PTN in OA cartilage could be interpreted as a mechanism
to restore cartilage integrity, especially of the extracellular
matrix. This hypothesis is sustained by the higher PTN
concentrations in the synovial fluid measured in early OA
(with partially still intact chondrocytes) as compared with
the values in late OA, when cartilage destruction is too high
to allow regenerative processes. Under this aspect, PTN
measurements in the synovial fluid could be used as an
additional parameter for the staging of OA.
Receptors for PTN and their signal transduction mecha-
nisms have not yet been fully characterized. So far, inter-
action of PTN with the receptor-type protein tyrosine
phosphatase ζ/β, anaplastic lymphoma kinase (ALK), and
syndecan-3 have been shown2,24–26. By disruption of the
normal balance between tyrosine kinase and phosphatase
activities, phosphorylation of intracellular proteins was
found to be increased24, in particular, that of β-catenin25
that is involved in transcription and transformation of the
cytoskeletal architecture, or that of downstream effector
molecules such as insulin receptor substrate IRS-1, Shc,
phospholipase C-γ, and phosphatidylinositol 3′-kinase26.
However, these mechanisms and the biological effects
differ significantly between the various target cell types.
PTN expression and effects have been primarily studied
during the embryogenesis. So far, the clinical interest for
PTN was in its expression in certain types of cancer,
especially in breast cancer, pancreatic cancer, and
melanoma10–13. Chronic inflammatory diseases like OA
have to be added to the list of pathological conditions
with PTN expression. It may depend on the tissue whether
PTN functions as a repair factor or an amplifier of
inflammation.
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